Valuation: AbbVie Inc.

Market Cap 489B 436B 406B 369B 697B 47,282B 700B 4,888B 1,912B 24,098B 1,834B 1,794B 77,335B P/E 2026 *
35.2x
P/E 2027 * 26.3x
Enterprise Value 549B 491B 456B 415B 784B 53,177B 787B 5,497B 2,151B 27,103B 2,063B 2,018B 86,977B EV / Sales 2026 *
8.13x
EV / Sales 2027 * 7.37x
Free-Float
95.71%
Yield 2026 *
2.51%
Yield 2027 * 2.61%
1 day+1.49%
1 week+5.19%
Current month+5.69%
1 month+8.42%
3 months+11.44%
6 months+32.96%
Current year+21.00%
1 week 260.29
Extreme 260.29
277.6
1 month 257.8
Extreme 257.795
277.6
Current year 190.75
Extreme 190.75
277.6
1 year 190.75
Extreme 190.75
277.6
3 years 135.85
Extreme 135.85
277.6
5 years 106.86
Extreme 106.86
277.6
10 years 55.06
Extreme 55.0623
277.6
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Free

Director

59 0.0000%
9/30/26 Free

Director

129 0.0000%
8/14/26 Exercice

Executive/Senior Manager

98,130 0.0056%
Change 5-day change 1-year change 3-year change Capi.($)
+1.49%+5.19%+19.94%+85.69% 489B
+0.83%+3.19%+41.49%+103.56% 1,051B
+1.93%+2.11%+37.08%+65.09% 630B
+2.26%+0.90%+69.32%+40.53% 359B
+1.45%+3.50%+23.29%+41.62% 344B
+1.17%+2.37%+13.47%+33.64% 272B
+0.89%+1.08%-6.13%+9.29% 246B
+1.82%+2.94%+42.99%+52.95% 224B
+2.77%+4.44%+29.01%+98.99% 187B
+2.14%+2.61%-32.29%-60.74% 169B
Average +1.68%+2.54%+23.82%+47.06% 397.28B
Weighted average by Cap. +1.50%+2.45%+30.56%+63.49%

Financials

2026 *2027 *
Net sales 67.6B 60.38B 56.15B 51.09B 96.42B 6,542B 96.8B 676B 265B 3,334B 254B 248B 10,701B 73.55B 65.69B 61.09B 55.59B 105B 7,118B 105B 736B 288B 3,628B 276B 270B 11,642B
Net income 14.42B 12.88B 11.98B 10.9B 20.57B 1,396B 20.65B 144B 56.44B 711B 54.14B 52.96B 2,283B 18.94B 16.92B 15.74B 14.32B 27.02B 1,833B 27.13B 190B 74.15B 934B 71.13B 69.58B 2,999B
Net Debt 60.91B 54.4B 50.59B 46.04B 86.88B 5,895B 87.22B 609B 238B 3,004B 229B 224B 9,641B 53.23B 47.54B 44.21B 40.23B 75.92B 5,151B 76.22B 533B 208B 2,625B 200B 195B 8,426B
Projected Income Statement - Annual - AbbVie Inc.
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-10-09 $276.47 +1.49% 4,297,946
26-10-08 $272.42 +0.39% 5,494,940
26-10-07 $271.36 +1.75% 6,079,078
26-10-06 $266.69 +0.35% 4,501,087
26-10-05 $265.76 +1.12% 7,544,505
Trader
Investor
Global
Quality
ESG MSCI
AAA
Ratings Surperformance© - AbbVie Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
276.47USD
Average target price
282.61USD
Spread / Average Target
+2.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AbbVie Inc.
  1. Stock Market
  2. Stocks
  3. ABBV Stock